Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pyridoxal. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.88 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.88 |
| ▸ | LMNA | P02545 | 6/20 | 0.88 |
| ▸ | HPGD | P15428 | 5/20 | 0.88 |
| ▸ | MEN1 | O00255 | 3/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.88 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.88 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.85 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.85 |
| ▸ | ESR1 | P03372 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | ACP1 | P24666 | 1/20 | 0.68 |
| ▸ | PDE4A | P27815 | 1/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.68 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.68 |
| ▸ | PDXK | O00764 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 6/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxal SCHEMBL9559097 | 1.00 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL27627958 | 1.00 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL28454700 | 1.00 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL18726347 | 1.00 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL5051301 | 1.00 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL30616198 | 1.00 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL27131 | 1.00 | KDM4E (0.88) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL8090165 | 0.98 | KDM4E (0.85) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL1065056 | 0.98 | KDM4E (0.85) | KDM4EALDH1A1LMNAHPGDMEN1 | |
| Pyridoxal SCHEMBL6701817 | 0.98 | KDM4E (0.85) | KDM4EALDH1A1LMNAHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3333266-B1 | METHOD FOR PRODUCING SELENONEINE | KIKKOMAN CORP (JP) | 2024-04-24 | — | — | EP | claimed |
| WO-2024090329-A1 | COMPOSITION FOR AMELIORATING INFLAMMATION ASSOCIATED WITH CHRONIC HYPOXIA | 国立大学法人東北大学 | 2024-05-02 | — | — | WO | disclosed |
| WO-2024013258-A1 | PRODUCTION OF CYSTEINE OR CYSTINE FROM SERINE IN FERMENTATION MEDIUM | CYSBIO APS (DK) | 2024-01-18 | — | — | WO | disclosed |
| US-20070148154-A1 | Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs | UNIVERSITE RENE DESCARTES (PARIS V) (FR) | 2007-06-28 | — | — | US | disclosed |
| EP-1694338-A2 | USE OF SUPEROXIDE DISMUTASE MIMETICS AND REDUCTASE GLUTATHIONE IN THE FORM OF ANTICANCER DRUGS | UNIVERSITE RENE DESCARTES, (PARIS V) (FR) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005060976-A2 | USE OF SUPEROXIDE DISMUTASE MIMETICS AND REDUCTASE GLUTATHIONE IN THE FORM OF ANTICANCER DRUGS | UNIVERSITE RENE DESCARTES (PARIS V) (FR) | 2005-07-07 | — | — | WO | disclosed |